Texas Instruments Incorporated (TXN) Bundle
Goldman Sachs Downgrades Texas Instruments to Sell on Capex
Goldman Sachs downgraded Texas Instruments (NASDAQ:TXN) from Buy to Sell on Dec 18, 2025. The investment firm lowered its 12-month price target for the semiconductor manufacturer to $156 from $200.
The downgrade follows concerns regarding the strategic capacity decisions and capital allocation of the company. Goldman Sachs analysts noted that these factors could weigh on margins and the recovery of earnings relative to industry peers.
Key data points from the report include:
- Texas Instruments maintained a 26% global market share in the analog semiconductor industry as of 2024.
- The revised price target of $156 implies a downside of approximately 13% from current market levels.
- Analysts identified over 40% upside potential for the median analog stock within the Goldman Sachs coverage universe.
While Goldman Sachs maintains a constructive outlook for a broader analog sector recovery in 2026, it expects Texas Instruments to face company-specific challenges. These idiosyncratic factors are projected to limit upside potential even as industry conditions improve.
For more information on the company operational background and financial status, refer to the TXN-history-mission-ownership and TXN-financial-health reports. Additional details are available in the TXN-mission-vision and TXN-investor-profile blogs.
Texas Instruments Incorporated (TXN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.